Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing incidence of cervical dysplasia
3.2.1.2 Expanding R&D funding and activities
3.2.1.3 Growing awareness and diagnosis
3.2.1.4 Improved diagnostic technologies
3.2.2 Industry pitfalls & challenges
3.2.2.1 Side effects and adverse reactions
3.2.2.2 Regulatory challenges
3.3 Growth potential analysis
3.4 Pipeline analysis
3.5 Regulatory landscape
3.6 Porters analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 High-grade cervical dysplasia
5.3 Low-grade cervical dysplasia
Chapter 6 Market Estimates and Forecast, By Diagnosis and Treatment, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Diagnosis
6.2.1 Pap smear test
6.2.2 HPV DNA test
6.2.3 Colposcopy
6.2.4 Biopsy
6.2.5 Other diagnosis tests
6.3 Treatment
6.3.1 Surgical treatment
6.3.1.1 Loop electrosurgical excision procedure (LEEP)
6.3.1.2 Cold knife conization (CKC)
6.3.1.3 Cryosurgery
6.3.1.4 Other surgical treatments
6.3.2 Non-surgical treatment
6.3.2.1 Topical medications
6.3.2.2 Immunotherapy
Chapter 7 Market Estimates and Forecast, By End-User, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Hospitals
7.3 Specialty clinics
7.4 Diagnostic centers
7.5 Other end-users
Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Netherlands
8.3.7 Rest of Europe
8.4 Asia Pacific
8.4.1 Japan
8.4.2 China
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.4.6 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Rest of Latin America
8.6 Middle East and Africa
8.6.1 Saudi Arabia
8.6.2 South Africa
8.6.3 UAE
8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
9.1 Abbott Laboratories
9.2 Asieris Pharmaceuticals
9.3 Becton, Dickinson and Company
9.4 F. Hoffmann-La Roche Ltd.
9.5 GlaxoSmithKline PLC
9.6 Hologic Inc.
9.7 Kinopharma
9.8 Merck & Co., Inc.
9.9 OncoHealth Corporation
9.10 Qiagen
